Sugi Predict

Sugi Predict / Compounds / SCHEMBL1674805

SCHEMBL1674805

SCHEMBL1674805

CC(C)C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CC(C)C)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NMUR2 Q9GZQ4 6/20 0.57
▸ NMUR1 Q9HB89 5/20 0.57
▸ OPRM1 P35372 1/20 0.55
▸ OPRD1 P41143 1/20 0.55
▸ OPRK1 P41145 1/20 0.55
▸ SLC6A2 P23975 1/20 0.53
▸ NTSR2 O95665 1/20 0.53
▸ NTSR1 P30989 1/20 0.53
▸ SORT1 Q99523 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1674802 1.00 NMUR2 (0.57) NMUR2NMUR1OPRM1OPRD1OPRK1
Leucine SCHEMBL14969488 0.98 NMUR2 (0.56) NMUR2NMUR1OPRM1OPRD1OPRK1
SCHEMBL28915426 0.97 NMUR2 (0.58) NMUR2NMUR1OPRM1OPRD1OPRK1
SCHEMBL28915423 0.97 NMUR2 (0.58) NMUR2NMUR1OPRM1OPRD1OPRK1
SCHEMBL22400261 0.94 OPRM1 (0.55) OPRM1OPRD1OPRK1SLC6A2NTSR2
SCHEMBL1674810 0.94 OPRM1 (0.55) OPRM1OPRD1OPRK1SLC6A2NTSR2
SCHEMBL1674814 0.94 OPRM1 (0.55) OPRM1OPRD1OPRK1SLC6A2NTSR2
SCHEMBL31377408 0.94 SLC6A2 (0.57) OPRM1OPRD1OPRK1SLC6A2
SCHEMBL30853506 0.91 NTSR2 (0.63) SLC6A2NTSR2NTSR1SORT1
SCHEMBL29679668 0.89 SLC6A2 (0.61) NMUR2NMUR1OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240108040-A1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2024-04-04 — — US disclosed
US-11758933-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2023-09-19 — — US disclosed
US-11357246-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2022-06-14 — — US disclosed
US-20210227863-A1 HIGH INTENSITY SWEETENERS SENOMYX, INC. 2021-07-29 — — US disclosed
EP-3763419-A1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES Anji Pharma (US) LLC (US) 2021-01-13 — — EP disclosed
US-10610500-B2 Chemosensory receptor ligand-based therapies ANJI PHARMA (US) LLC (US) 2020-04-07 — — US disclosed
US-10392371-B2 Compounds useful as modulators of TRPM8 SENOMYX, INC. (US) 2019-08-27 — — US disclosed
US-20190177308-A9 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX, INC. 2019-06-13 — — US disclosed
US-20190038576-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2019-02-07 — — US disclosed
US-20180273517-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX INC (US) 2018-09-27 — — US disclosed
US-20140030332-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2014-01-30 — — US disclosed
US-8609362-B2 G-proteins GIVAUDAN SA (CH) 2013-12-17 — — US disclosed
US-20130281387-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2013-10-24 — — US disclosed
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 — — US disclosed
US-20110177545-A1 G-PROTEINS GIVAUDAN SA (CH) 2011-07-21 — — US disclosed
US-7919236-B2 G-proteins GIVAUDAN SA (CH) 2011-04-05 — — US disclosed
EP-1581555-B1 CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS GIVAUDAN SA (CH) 2008-04-30 — — EP disclosed
US-20060275765-A1 G-proteins GIVAUDAN SA (CH) 2006-12-07 — — US disclosed
EP-1581555-A2 G-PROTEINS Givaudan SA (CH) 2005-10-05 — — EP disclosed
WO-2004055048-A2 CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS GIVAUDAN SA (CH) 2004-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108040-A1 HIGH INTENSITY SWEETENERS TAS2R40, TAS2R60, TAS1R1 NMUR2 1914/4885NMUR1 1635/4885OPRM1 2711/4885
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 NMUR2 178/4885NMUR1 154/4885OPRM1 189/4885
US-10610500-B2 Chemosensory receptor ligand-based therapies TAS1R2, TAS2R1, GPR119 NMUR2 178/4885NMUR1 154/4885OPRM1 189/4885
US-10392371-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM4, TRPM6 NMUR2 65/4885NMUR1 62/4885OPRM1 111/4885
US-11357246-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 NMUR2 1914/4885NMUR1 1635/4885OPRM1 2711/4885
US-20190177308-A9 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 TRPM8, TRPM6, TRPM4 NMUR2 48/4885NMUR1 63/4885OPRM1 96/4885
US-20180273517-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 TRPM8, TRPM6, TRPM4 NMUR2 48/4885NMUR1 63/4885OPRM1 96/4885
US-20130281387-A1 Chemosensory Receptor Ligand-Based Therapies GPR119, TAS1R2, TAS2R1 NMUR2 347/4885NMUR1 344/4885OPRM1 183/4885
US-20190038576-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 NMUR2 178/4885NMUR1 154/4885OPRM1 189/4885
US-20210227863-A1 HIGH INTENSITY SWEETENERS TAS2R40, TAS2R60, TAS1R1 NMUR2 1914/4885NMUR1 1635/4885OPRM1 2711/4885
US-11758933-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 NMUR2 1914/4885NMUR1 1635/4885OPRM1 2711/4885
US-20140030332-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 NMUR2 178/4885NMUR1 154/4885OPRM1 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.